Biotechnology · Nasdaq: BIIB
Biogen earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 5 Feb 2027
Latest: Q3 2026
Biogen's first full quarter with Apellis' eye and kidney drugs pushed growth products to 63% of core pharmaceutical revenue, ahead of December Phase 3 lupus readouts.
Biogen's growth products, led by SPINRAZA high-dose conversions, LEQEMBI and the newly acquired SYFOVRE and EMPAVELI, are now the center of the business while legacy multiple sclerosis drugs decline. LEQEMBI's subcutaneous autoinjector is drawing prescribers who never wrote an Alzheimer's antibody before. Management says Apellis integration is going faster than planned and that the company can now grow even without its pipeline.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.5B * |
| Q1 2025 | $2.4B |
| Q2 2025 | $2.6B |
| Q3 2025 | $2.5B |
| Q4 2025 | $2.3B * |
| Q1 2026 | $2.5B |
| Q2 2026 | $2.7B |
| Q3 2026 | $2.8B |
Data
| Q1 2025 | $1.64 |
| Q2 2025 | $4.33 |
| Q3 2025 | $3.17 |
| Q1 2026 | $2.15 |
| Q2 2026 | $0.66 |
| Q3 2026 | -$0.14 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | $721.6M |
| Q1 2025 | $222.2M |
| Q2 2025 | $134.3M |
| Q3 2025 | $1.2B |
| Q4 2025 | $468.0M |
| Q1 2026 | $594.3M |
| Q2 2026 | $408.0M |
| Q3 2026 | $600.4M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5Bd | $2.4B | $2.6B | $2.5B | $2.3Bd | $2.5B | $2.7B | $2.8B |
| Net income | $266.7Md | $240.5M | $634.8M | $466.5M | -$48.9Md | $319.5M | $97.5M | -$20.6M |
| Diluted EPS | — | $1.64 | $4.33 | $3.17 | — | $2.15 | $0.66 | -$0.14 |
| Operating cash flow | $760.9Md | $259.3M | $160.9Md | $1.3Bd | $511.9Md | $645.5M | $448.9Md | $640.8Md |
| Capital expenditure | $39.3Md | $37.1M | $26.6Md | $46.2Md | $43.9Md | $51.2M | $40.9Md | $40.4Md |
| Free cash flow | $721.6M | $222.2M | $134.3M | $1.2B | $468.0M | $594.3M | $408.0M | $600.4M |
| R&D expense | $513.3Md | $434.1M | $399.0M | $436.1M | $509.4Md | $539.0M | $529.6M | $574.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 28 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 29 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 29 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 6 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 31 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 12 Feb 202510-K for the period ended 31 Dec 2024SEC ↗